Which has stronger earnings and valuation, HQY or DXCM?

DexCom has higher revenue and earnings than HealthEquity. HealthEquity is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthEquity $1.31B 5.62 $215.20M $2.77 32.23 DexCom $4.66B 6.92 $836.30M $2.53 33.79

Is HQY or DXCM more profitable?

DexCom has a net margin of 20.12% compared to HealthEquity's net margin of 17.36%. DexCom's return on equity of 35.94% beat HealthEquity's return on equity. Company Net Margins Return on Equity Return on Assets HealthEquity 17.36% 15.33% 9.51% DexCom 20.12% 35.94% 14.75%

Does the media refer more to HQY or DXCM?

In the previous week, DexCom had 4 more articles in the media than HealthEquity. MarketBeat recorded 8 mentions for DexCom and 4 mentions for HealthEquity. DexCom's average media sentiment score of 0.44 beat HealthEquity's score of 0.13 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, DXCM or PODD?

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.92 $836.30M $2.53 33.79 Insulet $2.71B 3.35 $247.10M $5.35 24.43

Is DXCM or PODD more profitable?

DexCom has a net margin of 20.12% compared to Insulet's net margin of 12.29%. DexCom's return on equity of 35.94% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% Insulet 12.29% 29.29% 13.31%

Does the media refer more to DXCM or PODD?

In the previous week, Insulet had 1 more articles in the media than DexCom. MarketBeat recorded 9 mentions for Insulet and 8 mentions for DexCom. DexCom's average media sentiment score of 0.44 beat Insulet's score of 0.33 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insulet 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, ABT or DXCM?

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abbott Laboratories $44.33B 3.77 $6.52B $3.09 31.24 DexCom $4.66B 6.92 $836.30M $2.53 33.79

Does the media prefer ABT or DXCM?

In the previous week, Abbott Laboratories had 16 more articles in the media than DexCom. MarketBeat recorded 24 mentions for Abbott Laboratories and 8 mentions for DexCom. Abbott Laboratories' average media sentiment score of 0.51 beat DexCom's score of 0.44 indicating that Abbott Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 8 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive DexCom 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DXCM or AMN?

In the previous week, DexCom had 5 more articles in the media than AMN Healthcare Services. MarketBeat recorded 8 mentions for DexCom and 3 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.83 beat DexCom's score of 0.44 indicating that AMN Healthcare Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AMN Healthcare Services 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ITGR or DXCM?

DexCom has higher revenue and earnings than Integer. DexCom is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 2.32 $102.81M $3.66 34.56 DexCom $4.66B 6.92 $836.30M $2.53 33.79

Is ITGR or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Integer's net margin of 6.97%. DexCom's return on equity of 35.94% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Integer 6.97% 12.79% 6.48% DexCom 20.12% 35.94% 14.75%

Does the media prefer ITGR or DXCM?

In the previous week, DexCom had 3 more articles in the media than Integer. MarketBeat recorded 8 mentions for DexCom and 5 mentions for Integer. DexCom's average media sentiment score of 0.44 beat Integer's score of 0.27 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral DexCom 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

DexCom (DXCM) Competitors

$85.36 -0.87 (-1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$85.36 +0.00 (+0.01%)

As of 07:30 PM Eastern

Compare

DXCM vs. HQY, PODD, ABT, AMN, and ITGR

Should you buy DexCom stock or one of its competitors? DexCom's main competitors and comparable companies include HealthEquity (HQY), Insulet (PODD), Abbott Laboratories (ABT), AMN Healthcare Services (AMN), and Integer (ITGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does DexCom compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

HealthEquity currently has a consensus price target of $112.20, suggesting a potential upside of 25.66%. DexCom has a consensus price target of $89.74, suggesting a potential upside of 4.97%. Given HealthEquity's stronger consensus rating and higher probable upside, equities analysts clearly believe HealthEquity is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
DexCom	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.92

DexCom has a net margin of 20.12% compared to HealthEquity's net margin of 17.36%. DexCom's return on equity of 35.94% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	17.36%	15.33%	9.51%
DexCom	20.12%	35.94%	14.75%

HealthEquity has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, DexCom has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

In the previous week, DexCom had 4 more articles in the media than HealthEquity. MarketBeat recorded 8 mentions for DexCom and 4 mentions for HealthEquity. DexCom's average media sentiment score of 0.44 beat HealthEquity's score of 0.13 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.6% of HealthEquity shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.6% of HealthEquity shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

DexCom has higher revenue and earnings than HealthEquity. HealthEquity is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.31B	5.62	$215.20M	$2.77	32.23
DexCom	$4.66B	6.92	$836.30M	$2.53	33.79

Summary

DexCom beats HealthEquity on 12 of the 17 factors compared between the two stocks.

How does DexCom compare to Insulet?

DexCom (NASDAQ:DXCM) and Insulet (NASDAQ:PODD) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

DexCom has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Insulet has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Insulet had 1 more articles in the media than DexCom. MarketBeat recorded 9 mentions for Insulet and 8 mentions for DexCom. DexCom's average media sentiment score of 0.44 beat Insulet's score of 0.33 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insulet	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.8% of DexCom shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 0.4% of Insulet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.92	$836.30M	$2.53	33.79
Insulet	$2.71B	3.35	$247.10M	$5.35	24.43

DexCom has a net margin of 20.12% compared to Insulet's net margin of 12.29%. DexCom's return on equity of 35.94% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Insulet	12.29%	29.29%	13.31%

DexCom presently has a consensus target price of $89.74, indicating a potential upside of 4.97%. Insulet has a consensus target price of $195.40, indicating a potential upside of 49.51%. Given Insulet's higher probable upside, analysts plainly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.92
Insulet	2 Sell rating(s)	11 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.42

Summary

DexCom beats Insulet on 13 of the 17 factors compared between the two stocks.

How does DexCom compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Abbott Laboratories has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, DexCom has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Abbott Laboratories currently has a consensus target price of $119.80, suggesting a potential upside of 24.11%. DexCom has a consensus target price of $89.74, suggesting a potential upside of 4.97%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, research analysts plainly believe Abbott Laboratories is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	3 Strong Buy rating(s)	2.96
DexCom	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.92

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.77	$6.52B	$3.09	31.24
DexCom	$4.66B	6.92	$836.30M	$2.53	33.79

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Abbott Laboratories had 16 more articles in the media than DexCom. MarketBeat recorded 24 mentions for Abbott Laboratories and 8 mentions for DexCom. Abbott Laboratories' average media sentiment score of 0.51 beat DexCom's score of 0.44 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	8 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
DexCom	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DexCom has a net margin of 20.12% compared to Abbott Laboratories' net margin of 11.65%. DexCom's return on equity of 35.94% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	11.65%	17.69%	9.44%
DexCom	20.12%	35.94%	14.75%

Summary

Abbott Laboratories beats DexCom on 10 of the 17 factors compared between the two stocks.

How does DexCom compare to AMN Healthcare Services?

DexCom (NASDAQ:DXCM) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

DexCom has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

DexCom has a net margin of 20.12% compared to AMN Healthcare Services' net margin of 3.06%. DexCom's return on equity of 35.94% beat AMN Healthcare Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
AMN Healthcare Services	3.06%	19.92%	5.93%

97.8% of DexCom shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, DexCom had 5 more articles in the media than AMN Healthcare Services. MarketBeat recorded 8 mentions for DexCom and 3 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.83 beat DexCom's score of 0.44 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AMN Healthcare Services	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.92	$836.30M	$2.53	33.79
AMN Healthcare Services	$2.73B	0.52	-$95.70M	$2.68	13.71

DexCom presently has a consensus price target of $89.74, indicating a potential upside of 4.97%. AMN Healthcare Services has a consensus price target of $36.00, indicating a potential downside of 1.99%. Given DexCom's stronger consensus rating and higher probable upside, equities analysts clearly believe DexCom is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.92
AMN Healthcare Services	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

DexCom beats AMN Healthcare Services on 13 of the 17 factors compared between the two stocks.

How does DexCom compare to Integer?

Integer (NYSE:ITGR) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Integer has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, DexCom has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

In the previous week, DexCom had 3 more articles in the media than Integer. MarketBeat recorded 8 mentions for DexCom and 5 mentions for Integer. DexCom's average media sentiment score of 0.44 beat Integer's score of 0.27 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
DexCom	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.3% of Integer shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.1% of Integer shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

DexCom has a net margin of 20.12% compared to Integer's net margin of 6.97%. DexCom's return on equity of 35.94% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
DexCom	20.12%	35.94%	14.75%

DexCom has higher revenue and earnings than Integer. DexCom is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	2.32	$102.81M	$3.66	34.56
DexCom	$4.66B	6.92	$836.30M	$2.53	33.79

Integer presently has a consensus price target of $109.86, suggesting a potential downside of 13.14%. DexCom has a consensus price target of $89.74, suggesting a potential upside of 4.97%. Given DexCom's stronger consensus rating and higher probable upside, analysts clearly believe DexCom is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
DexCom	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

DexCom beats Integer on 13 of the 17 factors compared between the two stocks.

Get DexCom News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXCM vs. The Competition

Export

Metric	DexCom	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.21B	$5.36B	$7.09B	$13.24B
Dividend Yield	N/A	1.80%	2.53%	15.88%
P/E Ratio	33.74	24.66	274.61	26.05
Price / Sales	6.91	41.73	600.52	89.39
Price / Cash	31.16	32.68	77.38	51.25
Price / Book	12.13	5.68	10.92	6.31
Net Income	$836.30M	$152.11M	$3.50B	$361.43M
7 Day Performance	-1.45%	-2.01%	-2.11%	-1.67%
1 Month Performance	-4.83%	-5.42%	-6.34%	-3.94%
1 Year Performance	28.48%	2.75%	8.81%	2.77%

DexCom Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXCM DexCom	3.627 of 5 stars	$85.36 -1.0%	$89.74 +5.1%	+30.5%	$32.21B	$4.66B	33.74	11,000	Analyst Forecast Insider Trade
HQY HealthEquity	4.2218 of 5 stars	$88.44 +0.2%	$112.20 +26.9%	-1.5%	$7.31B	$1.31B	31.93	2,814
PODD Insulet	4.1489 of 5 stars	$133.11 -2.2%	$195.40 +46.8%	-57.3%	$9.23B	$2.71B	24.88	5,400
ABT Abbott Laboratories	4.9573 of 5 stars	$100.94 -0.3%	$119.50 +18.4%	-27.6%	$174.66B	$44.33B	32.67	115,000	Trending News Analyst Upgrade
AMN AMN Healthcare Services	1.4411 of 5 stars	$34.20 -1.0%	$36.00 +5.3%	+80.0%	$1.32B	$2.73B	12.76	2,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXCM) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Competitors